Sally Greenbrook, Breakthrough Breast Cancer
Media playback is unsupported on your device
Video

Breast cancer charity urges move to lower cost of Kadcyla

Cancer charity Breakthrough Breast Cancer has said more work needs to be done to make a new treatment available on the NHS in England.

The drugs advisory body, NICE, is proposing that Kadcyla will not be routinely available in England.

Kadcyla adds six months of life on average to women dying with an aggressive form of breast cancer.

NICE criticised makers Roche for not setting an affordable price - the drug costs £90,000 per patient.

Speaking to BBC Breakfast, Sally Greenbrook from Breakthrough Breast Cancer said manufacturer Roche and NICE must renegotiate arguing no-one benefits if the drugs "sit on a shelf".

  • 08 Aug 2014
  • From the section Health
Go to next video: Roche: 'Kadcyla is value for money'